塩に敏感な高血圧の実験における内皮機能不全と心臓・腎臓の損傷:抗高血圧療法による効果
1Department of Medicine, Veterans Affairs Medical Center and University of Minnesota Medical School, Minneapolis 55417, USA.
Circulation
|October 23, 1997
まとめ
利尿剤による高血圧治療は,血圧と心臓機能を正常化したが,腎臓の保護には至らなかった. コンビネーションセラピーは高血圧を効果的に治療し,心臓および腎臓システムを保護しました.
科学分野:
- 心血管研究 循環器科の研究
- ネフロロジーはネフロロジーを用います.
- 内皮機能の機能について
背景:
- 高血圧のコントロールは,心血管疾患による死亡率を低下させるが,心臓および腎臓の利益は控えめである.
- 内皮は,血管のトーン,血栓形成,再構成を調節する.
- 内皮機能不全は,高血圧における心肺神経損傷と関連しています.
研究 の 目的:
- 高血圧のラットにおける内皮機能障害と心肺神経損傷の関係を調査する.
- 利尿剤 (DIU) と ACE 阻害剤 (CEI) が高血圧に起因する心内損傷に及ぼす影響を評価する.
主な方法:
- ダール塩に敏感なネズミは,高塩分ダイエットによって高血圧を誘発された.
- 評価されたシストリック血圧 (SBP),内皮に依存したリラクゼーション (EDR),酸化窒素合成酵素活性,左心房高縮,球損傷,尿経タンパク質分泌.
- CEI (ペリンドプリル),DIU (インダパミド) または組み合わせ療法で治療されたラット.
主要な成果:
- 高血圧はEDRの障害,心筋縮,小球球球損傷,タンパク質尿と関連していました.
- CEI単独治療はEDRと腎臓のパラメータのわずかな改善を示したが,SBPを下げることはなかった.
- DIU単独治療は,SBP,EDR,心筋縮を正常化しましたが,腎臓の保護は限られています.
- 併用療法は,SBP,EDR,心筋縮を正常化し,腎臓のパラメータと球損傷を著しく改善しました.
結論:
- 抗高血圧療法では,内皮,心臓,腎臓への影響において解離が表れます.
- この解離は,異なる抗高血圧療法による心肺神経損傷の予防における異なった成功を説明する可能性がある.
関連する概念動画
Hypertension and Regulation of Blood Pressure
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Diuretics
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Hypertension II: Pathophysiology
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...


